Clinical Trials Logo
  1. Home
  2. Mastocytosis
  3. NCT02503800

The Significance of Blood-tryptase and c-Kit Mutation in Insect Venom Immunotherapy

Mastocytosis Clinical Trial

Official title:
The Significance of Blood-tryptase Levels and c-Kit Mutation in the Evaluation of Prognosis and Adverse Reactions in Subjects Undergoing Venom Immunotherapy for Insect Allergy

Clinical Trial Summary

The investigators wish to evaluate the association between tryptase values as well as c-Kit mutation and adverse effects in the course of immunotherapy. The investigators also intend to assess the effect of immunotherapy on tryptase levels.

Clinical Trial Description

According to the presently available reports there is an association between systemic allergic responses to hymenoptera venom and elevated tryptase levels or c-Kit mutation. The presence of these findings may imply the existence of mast cell activation syndrome or mastocytosis. Therefore, baseline tryptase evaluation has become standard evaluation in patients with systemic responses. Meir Medical Center is the only hospital in Israel in which tryptase can be measured. Consequently, the Meir Clinic has accumulated considerable data with regards to tryptase levels in subjects with allergy to hymenoptera venom. The investigators wish to evaluate the association between tryptase values as well as c-Kit mutation and adverse effects in the course of immunotherapy. The investigators also intend to assess the effect of immunotherapy on tryptase levels. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02503800
Study type Observational
Source Meir Medical Center
Contact
Status Completed
Phase
Start date August 2015
Completion date February 15, 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT01333293 - The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients Phase 2/Phase 3
Completed NCT01481909 - Study on Mastocytosis for Rupatadine Treatment Phase 2/Phase 3
Recruiting NCT00044122 - Study of Factors Regulating Mast Cell Proliferation
Recruiting NCT03340155 - Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases N/A
Not yet recruiting NCT05084872 - Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients Phase 2/Phase 3
Terminated NCT01701843 - Cromoglicate in Mastocytosis Phase 2
Completed NCT00831974 - Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis Phase 2
Completed NCT00047918 - Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing N/A
Completed NCT00006413 - Stem Cell Transplantation to Treat Systemic Mastocytosis Phase 2
Completed NCT00050193 - Cause and Natural Course of Pediatric-Onset Mastocytosis
Completed NCT02620254 - Mast Cell Connect: A Registry for Patients With Mastocytosis
Completed NCT00255346 - Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) Phase 2
Completed NCT00001356 - Characteristics of Mast Cells in Mastocytosis N/A
Recruiting NCT05186753 - (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis Phase 2
Completed NCT02478957 - Treatment of Indolent Systemic Mastocytosis With PA101 Phase 2
Recruiting NCT02450396 - Pregnancy and Medically Assisted Conception in Rare Diseases
Completed NCT00038675 - Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate N/A
Completed NCT00336076 - Molecular Mechanisms and Diagnosis of Mastocytosis N/A
Recruiting NCT04615663 - Assessment of Burden Disease in Patients With Mast Cell Disorders
Completed NCT00001760 - Cytokine Production Patterns in Patients With Systemic Mastocytosis Compared With Atopic Dermatitis and Healthy Individuals N/A